Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose RDN-929 study in healthy older adults and early symptomatic Alzheimer's disease
NL-OMON48424Completed
- Sponsor
- Rodin Therapeutics, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of RDN-929 in Alzheimer's disease (AD) (2 arms), sponsored by Rodin Therapeutics, Inc. Primary endpoint: Safety and tolerability. Started Jun 2019; status: completed.
02
Drugs
RDN-929
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON48424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48424.